Table 1 Demographic and clinical characteristics of study subjects
From: Insights into psychosis risk from leukocyte microRNA expression
| Â | Unaffected comparison (UC) n=29 | Clinical high risk, not psychotic (CHR-NP) n=37 | Clinical high risk, psychotic (CHR- P) n=30 |
|---|---|---|---|
Age, average (s.d.) | 19.3 (4.4) | 18.1 (3.8) | 18.7 (3.7) |
Ancestry | |||
 % Caucasian | 61%, | 65% | 52% |
 % African | 32% | 13.5% | 19% |
 % Asian | 7% | 13.5% | 19% |
 % Mixed | 0% | 8% | 10% |
Sex, % male | 68% | 62% | 74% |
SES, average (s.d.) | 7.5 (1.7) | 6.5 (1.7) | 6.2 (1.6) |
Peripheral blood mononuclear cells | |||
 Neutrophils % | 56 (11) | 55 (13) | 55 (10) |
 Lymphocytes % | 34 (9) | 35 (11) | 33 (9) |
 Monocytes % | 8 (2) | 7 (3) | 8 (3) |
 Eosinophils % | 2 (3) | 2 (2) | 2 (2) |
 Basophils % | 1 (1) | 1 (1) | 1 (1) |
SOPS scores, average (s.d.) | |||
 Totala | 4.8 (5.3) | 36.8 (12.4) | 45.0 (13.0) |
 Positivea | 1.3 (1.8) | 12.6 (4.4) | 13.9 (3.7) |
 Negativea | 1.3 (1.8) | 11.5 (5.9) | 14.0 (5.9) |
 Disorganizeda | .8 (1.1) | 4.9 (2.6) | 6.2 (3.4) |
Generala,b | 1.4 (1.7) | 7.8 (4.5) | 10.9 (4.7) |
Prescription medication | |||
 Antipsychoticc | 0% | 27% | 13% |
 Antidepressantd | 3% | 24% | 23% |
 Stimulant | 0% | 7% | 6% |
 Mood stabilizer | 0% | 0% | 3% |
 Benzodiazepinee | 0% | 3% | 13% |
 NSAID | 0% | 0% | 0% |
 Antibiotic | 0% | 0% | 0% |
Substance use | |||
 Tobacco usef | 7% | 30% | 39% |
 Alcohol use | 41% | 38% | 35% |
 Marijuana useg | 7% | 24% | 32% |
